Preoperative versus Intraoperative Intravenous Tranexamic Acid Efficacy in Reducing Blood Loss in Hip Fracture Surgeries: A Randomized Controlled Trial

Ahmed A. Mahmoud, Hani A. Bassioony, Ahmed A. Elsheikh

Department of Orthopaedics, Benha faculty of medicine, Benha University, Egypt.

Correspondence to: Ahmed A. Mahmoud, Department of Orthopaedics, Benha faculty of medicine, Benha University, Egypt.

Email: dr.ahmedhasham@gmail.com

Abstract:

Background: Hip fracture is common, with the reported lifetime prevalence of 20% for women and 10% for men. Despite recent advances in the techniques and instrumentation of orthopedic procedures, however, hip fracture surgery is still commonly associated with substantial blood loss, subsequent acute anaemia, and the need for transfusion. Postoperative anaemia in patients with hip fracture may lead to decreased ambulation, reduced functional independence and reduced walking distance on discharge.

Objective: To evaluate the efficacy of intraoperative vs. postoperative IV-TXA on postoperative blood loss following hip fracture surgery.

Patients and Methods: A prospective randomized controlled study that was held on thirty adult patients with hip fracture who had a surgery.

Results: The drains were removed in day 2. Mean volume of blood in the drain at day 0 was 140.00 ± 60.36 ml in group A as compared to 163.33 ± 66.73 ml in group B. Mean volume of blood in the drain at day 2 was 142.00 ± 85.54 ml in group A as compared 123.33 ± 56.27 ml in group B.

Conclusion: The present study demonstrated that there is no significant difference between preoperative versus intraoperative IV-TXA in reducing blood loss in patients undergoing surgeries for hip and proximal femoral fractures. Additionally TXA administration in both groups caused a reduction in postoperative anemia and need for transfusion without significantly increasing the risk of thromboembolic events including DVT. This would in turn, help to avoid complications related with transfusion of blood and blood products.

Keywords: Intravenous tranexamic acid, blood loss, hemoglobin
Introduction

Hip fracture is common, with the reported lifetime prevalence of 20% for women and 10% for men in the United States [1]. A national epidemiological study in China reported a higher incidence among older people [2]. Despite recent advances in the techniques and instrumentation of orthopedic procedures, however, hip fracture surgery is still commonly associated with substantial blood loss, subsequent acute anaemia, and the need for transfusion [3]. Postoperative anaemia in patients with hip fracture may lead to decreased ambulation, reduced functional independence and reduced walking distance on discharge [4]. Patients with anaemia have a lower recovery rate of physical disability than those without anaemia [5].

Thus, loads of techniques have been applied for blood management, including application of tourniquet, thromboplastic agents, topical freezing saline, deliberate hypotension, fibrinolytic inhibitors, blood transfusion and autologous donation [6]; of which, the allogeneic blood transfusion is the most commonly used strategy. In a previous study, the transfusion rate of allogeneic blood could reach as high as 84% [7]. However, allogeneic blood transfusion may increase the risk of adverse effects such as virus infection, immune response and cardiovascular dysfunction and even death, causing financial burden and a potential threat for patients [8]. Meanwhile, the current medical care standard recommends conservative and limited utilization of blood products [9], which underlines the need for better control of bleeding.

Tranexamic acid (TXA) is a synthetic amino acid that carries out its effects through an anti-fibrinolytic action. It stabilizes formed clots and prevents the degradation of fibrin by reversibly inhibiting the lysine binding site on plasminogen. It can destroy plasminogen's linkage with fibrin to become plasmin, which normally creates a fibrinolytic effect and dissolves clots [10]. Through reducing fibrinolysis, it helps to decrease bleeding and blood loss resulting from the trauma of surgery and the release of tissue plasminogen activator [11].

Recently, numerous studies have proved that intravenous (IV) TXA could reduce perioperative blood loss and transfusion requirements without increasing the risk of thrombosis during joint arthroplasty [12]. Also recent studies have reported that IV-TXA efficaciously reduces TBL and transfusion requirements during hip fracture surgery without significantly increasing the
risk of thromboembolic events including DVT\cite{13}.
Most of the included studies reported preoperative-only or preoperative plus postoperative IV-TXA, and the total dose ranged from 10 mg/kg to 1–4 g, so the optimal timing and dosage of IV-TXA are still unclear\cite{14}.
We conclude from the above the extent of importance of IV-TXA in reducing postoperative blood loss and transfusion requirements during hip fracture surgery, but the optimal timing of administration remains a perplexing matter. Therefore, we will address in this study the optimal timing of IV-TXA in hip fracture surgery, is it preoperative or intraoperative?

**Aim of the work**
The aim of this study is to evaluate the efficacy of intraoperative vs. postoperative IV-TXA on postoperative blood loss following hip fracture surgery.

**Patients and methods**
A prospective randomized controlled study held on thirty adult patients with hip fracture undergoing a surgery.

**Patients & study subjects:**
Inclusion criteria: (1) Patients with an established diagnosis of proximal femur fracture managed by DHS, DCS, proximal femoral plate or open reduction and nailing, (2) Patients with an established diagnosis of femoral neck fracture managed by hemiarthroplasty or primary total hip in case of acetabular problems and (3) Anatomical distribution in limbs: proximal femur and neck of Femur.
Exclusion criteria: (1) Patients with an established diagnosis of proximal femur fracture managed by closed reduction and nailing, (2) Polytrauma patients (two or more severe injuries in at least two areas of the body), (3) Patients allergic to TXA, (4) Preoperative renal impairment (creat. >2 mg%), (5) Preoperative hepatic impairment (INR>1.5 or liver enzymes elevated by > 3 times to normal range), (6) Known bleeding disorders or preoperative coagulation anomaly, (7) History of thromboembolic events such as MI, cerebrovascular accidents, PE, DVT or arterial thrombosis.
The study was carried out in Almataria teaching hospital from March 2020 to October 2020.
The study was approved by the institutional Ethics Committee and written informed consent was obtained from each patient.
Patients fulfilling the inclusion criteria are blindly divided into two groups.
Randomization was done by opaque sealed envelope technique.

**Group A:** receiving a bolus intravenous injection of (15 mg/kg) TXA through 50 ml syringe during 10 min about 15 min prior to skin incision.

**Group B:** receiving continuous infusion of 1 mg/kg/h TXA dissolved in 1 lit of saline until the completion of surgery.

Preoperatively, the hemoglobin concentration, bleeding time, clotting times were measured on the day before operation. The anesthetist administrating the drug was unaware of TXA being given. Surgery was performed under spinal anesthesia. Hemodynamics (heart rate, systolic, diastolic and mean arterial blood pressure (MABP)) was noted starting from preoperational to shifting at regular intervals of 30 min. Ringer's solution was used as the replacement fluid for the estimated intraoperative blood volume lost in a 3:1 ratio.

There was no significant difference in amount of fluid in both groups. A low-vacuum drain is inserted in the sub-muscular plane.

Postoperatively, All the following data were documented on day 0 (day of surgery at 20.00 hr) and day 2: Haemoglobin levels, volume of blood in the drain, the number of units of packed red cells transfused during the hospital stay. (The indication for blood transfusion is set at haemoglobin level <8.5 g/dl) and any thromboembolic and other complications are documented.

Statistical analysis was performed using SPSS 21.0 statistical software (SPSS Inc., Chicago, Ill., USA). Means are presented as mean ± standard deviation. T-test was used to compare numerical data, while measurement data was compared by Chi-square test. A p-value of less than 0.05 was considered significant.

**Results**

The mean age of the patients in group A was 62.27 ± 7.31 years and 61.93 ± 10.00 years in group B (p value 0.918). (53.3%) of the patients in group A were females and (46.7%) were males as opposed to (60.0% females) and (40.0% males) in group B (p value 0.136). The mean preoperative haemoglobin 11.93 ± 1.52 gm % in group A as compared to 12.39 ± 1.69 gm % in group B (p value -0.771) (Table 1). There were no significant differences between the patients with respect to age, sex and preoperative mean hemoglobin concentration.

The drains were removed in day 2. Mean volume of blood in the drain at day 0 was 140.00 ± 60.36 ml in group A as compared to 163.33 ± 66.73 ml in group B showing no statistically significant difference in postoperative blood loss (P value 0.324). Mean volume of blood in the drain at day 2
was 142.00 ± 85.54 ml in group A as compared 123.33 ± 56.27 ml in group B showing no statistically significant difference in postoperative blood loss (P value 0.486) (Table 2). Mean hemoglobin level at day 0 was 10.53 ± 1.54 gm % in group A as compared to 10.63 ± 1.86 gm % in group B that has P value 0.873 showing no statistically significant difference. Mean hemoglobin level at day 2 was 9.95 ± 1.25 gm % in group A as compared to 10.38 ± 1.32 gm % in group B that has P value 0.362 showing no statistically significant difference. In our study out of 30 patients, 10 patients required blood transfusion and Table (2) shows there was no statistically significant difference found between group A and group B as regarding blood transfusion in day 0 and the same in day 2.

Table 3 shows comparison between (preoperative vs day0 vs day 2) regarding HB in group A and group B and this table shows there was highly significant difference found between (preoperative Vs day 0) and (preoperative vs day 2) in group A and group B and also shows there was no significant difference found between (day 0 vs day 2) regarding HB in both groups.

No significant complications like thromboembolic episodes were encountered in both groups

Table 1:

<table>
<thead>
<tr>
<th></th>
<th>Group A (Pre TXA)</th>
<th>Group B (Intra TXA)</th>
<th>Test value</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. = 15</td>
<td>No. = 15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>Mean±SD</td>
<td></td>
<td>0.104•</td>
<td>0.918</td>
<td>NS</td>
</tr>
<tr>
<td>Range</td>
<td>62.27 ± 7.31</td>
<td>61.93 ± 10.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>50 – 80</td>
<td>45 – 81</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td></td>
<td>0.136*</td>
<td>0.713</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>8 (53.3%)</td>
<td>9 (60.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7 (46.7%)</td>
<td>6 (40.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre operative Hb</td>
<td>Mean±SD</td>
<td></td>
<td>-0.771•</td>
<td>0.447</td>
<td>NS</td>
</tr>
<tr>
<td>(g/dL)</td>
<td>11.93 ± 1.52</td>
<td>12.39 ± 1.69</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>10 – 15</td>
<td>10 – 16</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2:

<table>
<thead>
<tr>
<th></th>
<th>Group A (Pre TXA)</th>
<th>Group B (Intra TXA)</th>
<th>Test value•P-value Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. = 15</td>
<td>No. = 15</td>
<td></td>
</tr>
<tr>
<td><strong>Day 0</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HB g/dL Mean±SD</td>
<td>10.53 ± 1.54</td>
<td>10.63 ± 1.86</td>
<td>-0.161 0.873 NS</td>
</tr>
<tr>
<td>Range</td>
<td>8 – 12.2</td>
<td>7.9 – 13</td>
<td></td>
</tr>
<tr>
<td>Drain (ml) Mean±SD</td>
<td>140.00 ± 60.36</td>
<td>163.33 ± 66.73</td>
<td>-1.004 0.324 NS</td>
</tr>
<tr>
<td>Range</td>
<td>50 – 300</td>
<td>50 – 300</td>
<td></td>
</tr>
<tr>
<td>BL Mean±SD</td>
<td>625.00 ± 250.00</td>
<td>750.00 ± 288.68</td>
<td>-0.655 0.537 NS</td>
</tr>
<tr>
<td>Range</td>
<td>500 – 1000</td>
<td>500 – 1000</td>
<td></td>
</tr>
<tr>
<td><strong>Day 2</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HB g/dL Mean±SD</td>
<td>9.95 ± 1.25</td>
<td>10.38 ± 1.32</td>
<td>-0.926 0.362 NS</td>
</tr>
<tr>
<td>Range</td>
<td>6.9 – 12</td>
<td>8.4 – 12.5</td>
<td></td>
</tr>
<tr>
<td>Drain (ml) Mean±SD</td>
<td>142.00 ± 85.54</td>
<td>123.33 ± 56.27</td>
<td>0.706 0.486 NS</td>
</tr>
<tr>
<td>Range</td>
<td>50 – 350</td>
<td>50 – 200</td>
<td></td>
</tr>
<tr>
<td>BL Mean±SD</td>
<td>1000.00 ± 0.00</td>
<td>500.00 ± 0.00</td>
<td>- - -</td>
</tr>
<tr>
<td>Range</td>
<td>1000 – 1000</td>
<td>500 – 500</td>
<td></td>
</tr>
</tbody>
</table>

P-value >0.05: Non significant (NS); P-value <0.05: Significant (S); P-value< 0.01: highly significant (HS) •: Independent t-test

Post Hoc analysis by Bonferroni

<table>
<thead>
<tr>
<th></th>
<th>Pre-operative Vs Day 0</th>
<th>Pre-operative Vs Day 2</th>
<th>Day 0 Vs Day 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.000</td>
<td>0.000</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>0.000</td>
<td>0.002</td>
<td>0.500</td>
<td></td>
</tr>
</tbody>
</table>

P-value >0.05: Non significant (NS); P-value <0.05: Significant (S); P-value< 0.01: highly significant (HS) ‡: Mann Whitney test
Discussion

To our knowledge this would be the first study to compare preoperative IV TXA versus intraoperative IV TXA. We found that there is no significant difference between preoperative versus intraoperative IV-TXA in reducing blood loss in hip fracture surgeries.

The present study is a prospective randomized controlled study on 30 patients who underwent hip fracture surgeries. This coincides with several studies (15-18) which were also randomized controlled studies which compared TXA to control on patients who underwent hip fracture surgeries. However, other studies (19 & 20) were retrospective studies to evaluate the efficacy and safety of IV TXA in hip fracture surgeries with no controls.

We have included ORIF of proximal femoral fractures, hemiarthroplasty and primary THR, in agreement with others (15, 16, 17 & 18). While other studies were conducted solely on THR or TKR (21-22).

In the present study we have compared between two groups both received IV TXA to determine the optimal time to take it during hip fracture surgeries, while most of other studies (15, 17, 18 & 23) compared TXA to control group to evaluate the efficacy and safety of IV TXA in hip fracture surgeries. These studies concluded that IV TXA reduces transfusion requirements, total blood loss and without increasing the incidence of thromboembolic events in patients undergoing hip surgeries. Other studies (17 & 24) assessed the efficacy of topical TXA.

Some researchers (17) investigated 137 patients who underwent peritrochanteric fracture surgery divided into 2 groups. One group received 2 gm of topical and sub-facial infiltration of TXA. A study was conducted on 200 patients (24) who underwent intertrochanteric fracture surgery by intramedullary nail. The patients in the treatment group received 3g of tranexamic acid in the sub-fascial plane and around the fracture site. Forty three % reductions in transfusion requirements was reported (24) in contrast to a different study (17) where no any significant difference between 2 groups was reported.

In most of reported studies as well as the present study, the effect of IV tranexamic acid was assessed based on various parameters related to blood loss like drain...
output, haemoglobin drop and requirement for blood transfusion during surgeries for fixation of hip fractures.

In the present study there was no significant difference between the two groups in postoperative blood loss either in day 0 and in day 2. Also we found that there is no statistically significant difference between two groups as regard mean haemoglobin level and transfusion requirements. In atrial group, IV TXA was given preoperatively (15, 18 & 25). There was highly significant reduction in the Postoperative blood loss in TXA group. Also mean haemoglobin level and transfusion requirements were significantly better in the TXA group in all of these studies.

In a related study, 77 patients with intertrochanteric fracture were treated by PFNA received IV TXA preoperatively in TXA group and normal saline in control group. Postoperative blood loss has no significant difference between the two groups. However, postoperative transfusion rate was significantly lower in the TXA group compared to the control group versus control (P = 0.01) (27).

In a study published 2018, (16) 50 of 100 patients underwent intertrochanteric fracture surgery (PFNA) received IV TXA 15 min before surgery and 5 hrs postoperatively (TXA group) and other 50 received normal saline (control group). There was statistically significant difference in postoperative blood loss, haemoglobin and transfusion requirements in both groups. These results were achieved also in another study (28) in which IV TXA was given preoperatively and intraoperative infusion until surgery completion.

A study was conducted on cementless THR (26), and found a significant reduction in postoperative blood loss in TXA group than in the control group as well as in hemoglobin and hematocrit values. This coincides with the study conducted on 42 patients who underwent TKR showing high significant difference between 2 groups as regard postoperative blood loss (21).

As regard thromboembolic complications of TXA like DVT, pulmonary embolism, acute coronary syndrome, or myocardial infarction, we did not report any abnormal finding in both groups during the follow up. This comes in agreement with other studies (15, 17 & 18) where no patient had thromboembolic adverse events.

In other studies, three patients in the TXA group experienced DVT in the lower limbs, compared with two patients in the control
group with no statistically significant difference between the two groups. Also in lei et al two patients in TXA group presented by DVT in the lower limbs, although our study is prospective, it has certain limitations; the sample size is relatively small. The present study was not double-blinded. The surgeries were not performed by a single surgeon, thereby leading to differential expertise amongst different surgeons. We looked for the side effects of tranexamic acid only up to two weeks when the patient reported for suture removal. Any potential complications that could have presented later have not been accounted for. We could also not compare our results to the use of combined intravenous and local tranexamic acid. A larger randomized controlled trial might be needed to confirm our findings.

**Conclusion**

The present study demonstrated that there is no significant difference between preoperative versus intraoperative IV-TXA in reducing blood loss in patients undergoing surgeries for hip and proximal femoral fractures. Additionally TXA administration in both groups caused a reduction in postoperative anemia and need for transfusion without significantly compared with one patient in the control group with no statistically significant difference between the two groups (16) increasing the risk of thromboembolic events including DVT. This would in turn, help to avoid complications related with transfusion of blood and blood products.

**References**


To cite this article: Ahmed A. Mahmoud, Hani A. Bassioony, Ahmed A. Elsheikh. Preoperative Versus Intraoperative Intravenous Tranexamic Acid Efficacy in Reducing Blood Loss in Hip Fracture Surgeries: A Randomized Controlled Trial. BMFJ XXXX, DOI: 10.21608/bmfj.2021.52955.1360